Multinational study of 47 studies of 11,085 #RA pts showed the prevalence of ANXIETY to range from 2.4% to 77%. Variance due to inconsistent, non-standardized self-report measures and clinical thresholds. Common; but how common? https://t.co/elcxjfSI7N https://t.co/iRNeQy4pEk

Network metanalysis review of 65 trials (n=5957) looked at Tx effect in Hand #OA. Whereas oral NSAIDs & glucocorticoids’ NMA were effective compared with placebo; intraarticular steroid & hyaluronate, and HCQ and topical NSAIDs were NOT. https://t.co/8CCkfWd80E https://t.co/jpqlq8Xwgp

QD Clinic: Difficult #PMR Considerations Featuring Dr. Sarah Mackie (Leeds, UK) Difficulty weaning prednisone leads to consideration of other confounders and conditions QD Clinics are video vignettes with lessons from the clinic. https://t.co/H6cZaMperr @Sarah_L_Mackie https://t.co/WtCX6xfWe3

Gout Flare Prophylaxis - Colchicine or NSAIDs? A new study suggests that colchicine, more so than non-steroidal anti-inflammatory drug (NSAID) prophylaxis, may increase the odds of adverse events, when initiating allopurinol for gout. https://t.co/MfVvBy0DsD https://t.co/jP5oiAHaBa

Subclinical vasculitis in PMR For a long time #PMR has been an underinvestigated disease. This is changing with new possibilities to make a more accurate diagnosis with imaging as well as new therapies for treatment resistant disease. https://t.co/t0BRosgMWt https://t.co/bWZzRidqlm

Subclinical GCA prevalence in newly Dx #PMR ranges from 23 to 29%; best by Vessel imaging or temporal artery Bx. #PMR & GCA share common genetic/pathogenic inflammatory mechanisms & an IL-6 signature; BUT there are differences; further research needed! https://t.co/MhuIs068NG https://t.co/1BeeP3RY0H

GCA pts w/ prior #PMR Dx had 2 fold more Lg vessel dz & signif more vasculitic stenoses. Study of 311 GCA pts, 16% had prior PMR ~ 31 mos before. prior PMR had more LVV (51 vs 25%) & stenosis(18 vs 3%). Prior PMR incr LVV (OR 7.65) https://t.co/1kqtkPnPaz https://t.co/oVs084NfmV

JAKi Safety & Efficacy in bDMARD-IR Patients with RA: Results Through 5 Years This poster shows 5-year outcomes from the SELECT-BEYOND study in bDMARD-IR patients with RA, including TNFi-IR subgroup outcomes. Sponsored by AbbVie US Medical Affairs https://t.co/BRsCMnOnFT . https://t.co/lxfPs12mHb

X-sectional case-cntrl study w/ UK Biobank looked @ comorbidity w #PMR (n=1036) & GCA (102) pts (98% W; age 63 yrs) - pts rated their health as poor. Comorbid Dx included-more hypothyroidism (OR 1.34), HRT use (1.26), HTN (1.21-1.86) & cataract (1.51-3.84) https://t.co/GxpzN5NWug https://t.co/8J0IRMLK5g

New download on #PMR available now! https://t.co/C4fCUQ5j8e https://t.co/3Fm5xG8EM7

Steroid Tapering in #PMR: What's the Gold Standard? Dr. Anisha Dua, Chicago, discusses the gold standard tapering of glucocorticoids in polymyalgia rheumatica. https://t.co/WyojhJQkN2 https://t.co/NarFqwNxEj